产品名称	NCI-H1975人肺腺癌细胞
货号	ZQ0395
产品介绍	这株NCI-H1975 [H-1975，H1975]细胞是1988年从患有非小细胞肺癌的不吸烟女性的肺中分离的呈现上皮形态学的细胞系。 注意事项： NCI-H1975细胞在培养过程中细胞形态呈不规则上皮样和圆细胞两种形态，密度越高圆形细胞会增加，细胞胞体上有很多黑色颗粒，并且分泌出黑色颗粒是正常现象。
种属	人
性别/年龄	女
组织	肺
疾病	腺癌；非小细胞肺癌
细胞类型	肿瘤细胞
形态学	上皮的
生长方式	贴壁
倍增时间	大约28~42.2小时
培养基和添加剂	PMI-1640基础培养基（品牌：中乔新舟 货号：ZQ-200）+10%FBS（品牌：中乔新舟 货号：ZQ0500）+1%P/S（中乔新舟  货号：CSP006）+1%L-alanyl-L-glutamine（中乔新舟  货号：CSP004 ）+1%Sodium Pyruvate 100 mM Solution（中乔新舟   货号：CSP003）
推荐完全培养基货号	ZM0395
生物安全等级	BSL-1
STR位点信息	Amelogenin: X; CSF1PO: 12; D13S317: 10,13; D16S539: 9,12; D5S818: 11,12; D7S820: 8,11; THO1: 7; TPOX: 8,11; vWA: 18
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达	***
基因表达	***
保藏机构	ATCC; CRL-5908
供应限制	仅供科研使用

货号	ZQ0395
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： NEDD4L-induced ubiquitination mediating UBE2T degradation inhibits progression of lung adenocarcinoma via PI3K-AKT signaling
DOI： 10.1186/s12935-021-02341-9
发表时间： 2021-11-27
期刊： Cancer Cell International
影响因子： 5.722
货号： ZQ0395
产品名称： H1975 cell

原文链接： https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-02341-9

论文标题： LncRNA PCBP1-AS1 correlated with the functional states of cancer cells and inhibited lung adenocarcinoma metastasis by suppressing the EMT progression
DOI： 10.1093/carcin/bgab047
发表时间： 2021-07-16
期刊： CARCINOGENESIS
影响因子： 4.944
货号： ZQ0395
产品名称： H1975 cell
原文链接： https://academic.oup.com/carcin/advance-article-abstract/doi/10.1093/carcin/bgab047/6295508

 论文标题： Lobaplatin Enhances Radioactive 125I Seed-Induced Apoptosis and Anti-Proliferative Effect in Non-Small Cell Lung Cancer by Suppressing the AKT/mTOR Pathway
DOI： 10.2147/OTT.S288012
发表时间： 2021-01-12
期刊： OncoTargets and Therapy
影响因子： 4.147
货号： ZQ0395
产品名称： H1975 cell
原文链接： https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811486/

论文标题： Correlations of the ZEB1 expression with the incidence and prognosis of non-small cell lung cancer.
DOI： 10.26355/eurrev_201902_17111
发表时间： 2019-02-01
期刊： European Review for Medical and Pharmacological Sciences
影响因子： 2.721
货号： ZQ0395
产品名称： NCI-H1975 cells
原文链接： https://europepmc.org/article/med/30840275?javascript_support=no

PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339
Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K.
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Cancer Res. 67:2046-2053(2007)

PubMed=18083107; DOI=10.1016/j.cell.2007.11.025
Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Cell 131:1190-1203(2007)

PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S.P., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)

PubMed=21498706
Onitsuka T., Uramoto H., Tanaka F.
Lack of direct association between EGFR mutations and ER beta expression in lung cancer.
Anticancer Res. 31:855-860(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)

PubMed=25008024; DOI=10.1007/s10735-014-9583-2
Wang J., Wei H., Zhao B.-X., Li M., Lv W.-P., Lv L., Song B., Lv S.
The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
J. Mol. Histol. 45:641-652(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25483995; DOI=10.3892/mmr.2014.3058
Zhao B.-X., Wang J., Song B., Wei H., Lv W.-P., Tian L.-M., Li M., Lv S.
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
Mol. Med. Rep. 11:2767-2774(2015)